Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial : The Lancet
Links shared publicly online about this topic.
- 450total visits
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial : The Lancet
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase ...
View full resource at thelancet.com
Tags: Diabetes, Insulin, Type 2 Diabetes, Phase 2 Clinical Trial
Most Recently Shared on March 10, 2011 at 10:27 am By:
Insulin degludec once a day or three times a week compared with insulin glargine once a day http://fb.thelancet.com/JSY #diabetes
Family Medicine Article | Diabetes Mellitus, Type 2
mdlinx.com — “Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial” View full resource at mdlinx.com
Most Recently Shared on March 11, 2011 at 3:54 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insul... http://bit.ly/ew6IAe #FamPractice
Advertisement
